Ine Third line Very first line Second/ Thirdline Initially line Second/third line Masking Double blind Double blind Open label Open label Double blind Open label Open label Double blind Double blind Double blind Double blind Double blind Double blind Double blind Open label Double blind Double blind Major endpoint OS OS OS OS OS PFS Arm Cisplatin + fluoropyrimidine + Trastuzumab vs. Placebo Trastuzumab + cisplatin + fluoropyrimidine + Pertuzumab vs. Placebo T-DM1 vs. Taxane Lapatinib vs. Paclitaxel Capecitabine + oxaliplatin + Lapatinib vs. Placebo Capecitabine and cisplatin + Cetuximab vs. Placebo Status Outcomes Finished Good Ongoing Unknown Ongoing Unknown Finished Unfavorable Completed Negative Completed Damaging Ongoing Unknown Finished Unfavorable Completed Constructive Ongoing Unknown Ongoing Unknown Finishes PositiveFrequency of pT3/T4 EOX (epirubicin/oxaliplatin/capecitabine) categories just after surgery OS OS OS PFS PFS PFS PFS DCR OS OS Capecitabine + cisplatin + Bevacizumab vs. Placebo and BSC + Ramucirumab vs. Placebo Paclitaxel + Ramucirumab vs. Placebo mFOLFOX6+ Ramucirumab vs. Placebo Placebo vs.Apatinib placebo vs. apatinib mFOLFOX6 + Aflibercept vs. Placebo Tivantinib mFOLFOX6 + Onartuzumab vs. Placebo Everolimus vs. PlaceboOngoing Unknown Ongoing Unknown Finished Modest efficacy Ongoing Unknown Completed Unfavorable Web page 2 ofAbbreviation: HER2 human epidermal growth element receptor-2, OS all round survival, EGFR epidermal development aspect receptor, PFS progression totally free survival, VEGF vascular endothelial development issue, BSC most effective supportive care, DCR disease control rate, m-TOR mammalian target of rapamycinm.Qiu and Xu Biomarker Study 2013, 1:32 http://biomarkerres.org/content/1/1/Page 3 ofmetastasis rate [17-19]. Even so, the association amongst HER2 status and prognosis in gastric cancer remains controversial. Inside a few studies a correlation amongst HER2 amplification or overexpression and favorable survival was shown [20,21]. Within a retrospective analysis from 4 Chinese clinical centers, the HER2 status of 726 gastric cancer patients with all stages was detected. They found that HER2 was not a prognostic issue for gastric cancer sufferers [22]. A systematic analysis of data from the literature indicated that there was a clear trend towards a potential part for HER2 as a damaging prognostic factor in gastric cancer individuals [23].Trastuzumabtrastuzumab + cisplatin + fluoropyrimidine + pertuzumab vs. placebo . Main endpoint was OS. The outcome of this study is worth searching forward to [27].T-DMIn the ToGA trial, the addition of trastuzumab to chemotherapy drastically improved OS compared with chemotherapy alone in individuals with HER2-positive AGC.Buy5-Bromobenzene-1,3-diamine The HER2 positive rate was 22.Formula of 4-Iodobenzene-1,2-diol 1 within this study.PMID:33545151 The median OS was enhanced considerably within the trastuzumab arm compared using the handle arm [13.5 vs. 11.1 months, P = 0.0048; hazard ratio (HR), 0.74; 95 confidence interval (CI), 0.60 to 0.91]. In subgroup analysis, the individuals with HER2 immunohistochemistry (IHC) 2+/fluorescence in situ hybridization + or IHC 3+ had a longer OS compared with the chemotherapyalone arm (16 months vs. 11.eight months). In addition, the addition of trastuzumab to chemotherapy in the ToGA trial was well-tolerated, with no variations in the incidence of grade three or 4 adverse events (AEs) in between the two groups [9]. Based on the result of ToGA study, trastuzumab with chemotherapy was suggested for HER2 overexpressing AGC (category 1 for combination with cisplatin and fluorop.